Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242199 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 182
- Enrollment target
NCT04242199 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 182 participants.
The verdict
NCT04242199, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 182 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
Interventions
- DRUG INCB099280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2020-09-04 |
| Est. Completion | 2024-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04242199
The ClinicalTrials.gov registry entry for NCT04242199 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB099280 is the first listed.
NCT04242199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04242199 about?
NCT04242199 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
What is the current status of trial NCT04242199?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 182 participants. The study started on 2020-09-04. Estimated completion is 2024-11-21.
What interventions are being tested in trial NCT04242199?
The interventions under investigation include: INCB099280 (DRUG).
Who is sponsoring clinical trial NCT04242199?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.